The Merits of Awake Craniotomy for Glioblastoma in the Left Hemispheric Eloquent Area: One Institution Experience

CURRENT STATUS: UNDER REVIEW

BMC Neurology  BMC Series

Ying-Ching Li
Chang Gung Memorial Hospital

ORCiD: https://orcid.org/0000-0001-6789-4211

Hsiao-Yean Chiu
Chang Gung Memorial Hospital

Ya-Jui Lin
Chang Gung Memorial Hospital

Ko-Ting Chen
Chang Gung Memorial Hospital

Peng-Wei Hsu
Chang Gung Memorial Hospital

Yin-Cheng Huang
Chang Gung Memorial Hospital

Pin-Yuan Chen
Chang Gung Memorial Hospital

✉ pinyuanc@cgmh.org.tw Corresponding Author

Kuo-Chen Wei
Chang Gung Memorial Hospital

DOI: 10.21203/rs.2.15627/v2

SUBJECT AREAS

Neurosurgery  Oncology

KEYWORDS
Awake craniotomy, eloquent area, glioblastoma, KPS, PFS, OS
Abstract
Background Awake craniotomy (AC) with intraoperative stimulation mapping is the standard
treatment for gliomas, especially those on the eloquent cortex. Many studies have reported survival
benefits with the use of AC in patients with glioma, however most of these studies have focused on
low-grade glioma. The aim of this study was to evaluate the experience of one treatment center over
10 years for resection of left hemispheric eloquent glioblastoma.

Methods This retrospective analysis included 48 patients with left hemispheric eloquent glioblastoma
who underwent AC and 61 patients who underwent surgery under general anesthesia (GA) between
2008 and 2018. Perioperative risk factors, extent of resection (EOR), preoperative and
postoperative Karnofsky Performance Score (KPS), progression-free survival (PFS) and overall survival
(OS) were assessed.

Results The postoperative KPS was significantly lower in the GA patients compared to the AC patients
(p=0.002). The EOR in the GA group was 90.2% compared to 94.9% in the AC group (p=0.003). The
mean PFS was 18.9 months in the GA group and 23.2 months in the AC group (p=0.001). The mean
OS was 25.5 months in all patients, 23.4 months in the GA group, and 28.1 months in the AC group
(p<0.001). In multivariate analysis, the EOR and preoperative KPS independently predicted better OS.

Conclusion The patients with left hemispheric eloquent glioblastoma in this study had better
neurological outcomes, maximal tumor removal, and better PFS and OS after AC than surgery under
GA. Awake craniotomy should be performed in these patients if the resources are available.

Background
Achieving maximal surgical resection in patients with a supratentorial glioma has been shown to have
a positive effect on overall survival (OS). The most difficult challenge in cases of
gliomas located in eloquent regions of the cortex is to find a balance between maximizing tumor
resection and preserving surrounding functional structures. The traditional method of debulking a
tumor from within, which has been used for a long time in glioma surgery in order to avoid new
neurological deficits, can still lead to such deficits due to functional tissue being contained inside the
tumor. To overcome this problem, awake craniotomy (AC) allows for surgical mapping of
sensorimotor and language functions by directly stimulating the cortical and subcortical areas that are in proximity to or even inside the tumor, and it has been shown to enhance safety and maximize the extent of resection of tumors in eloquent regions of the brain.\textsuperscript{13,14,15} AC has enabled removal of tumors from highly functional eloquent regions that were once considered to be inoperable.\textsuperscript{16} Surgical resection reduces tumor burden, relieves symptoms caused by the tumor mass effect, and has been proven to be a prognostic factor for survival in glioma patients. Moreover, the improved survival in glioma patients treated with AC has been attributed to a maximized extent of resection (EOR). Many studies have reported the benefits of how AC can improve the survival of patients with glioma. However, most of these studies have focused on low-grade glioma, and few studies have reported patients with high-grade glioma or glioblastoma, and some studies have included a mix of tumor pathologies. In this study, we aimed to evaluate the experience of one treatment center over 10 years for resection of left hemispheric eloquent glioblastoma using direct brain stimulation and neuromonitoring with either AC or surgery under general anesthesia (GA). We compared the EOR and postoperative functional outcomes between the two methods. This represents the largest comparative study of AC and surgery under GA for treatment focused on glioblastoma located in left hemispheric eloquent areas in the literature.

\textbf{Methods}

\textbf{Patient Selection}

A list of patients with a diagnosis of glioma from June 2008 to December 2018 was requested from Chang Gung Memorial Hospital Cancer Center, and 1054 glioma patients who had undergone tumor resection surgery at Chang Gung Memorial Hospital, Linkou Branch, from 2010 to 2018 were collected. The inclusion criteria were: (1) age $\geq$ 18 years, (2) WHO grade IV glioblastoma in the left hemispheric eloquent area, defined as a tumor within or involving the primary motor cortex, primary sensory cortex, premotor cortex, and language cortex (Broca’s area or Wernicke’s area) based on magnetic resonance imaging (MRI), (3) an elective procedure, (4) a single lesion, and (5) new onset tumor. Patients who underwent a diagnostic biopsy alone, without pathological proof, and those < 18 years of age were excluded from the analysis. A total of 48 patients who underwent AC were included.
in this study. In addition, 61 patients who underwent craniotomy under GA with neuromonitoring (motor evoked potentials, somatosensory evoked potentials, phase reversal) were also included in this study. The patients’ characteristics, treatment course and follow-up status were reviewed via electronic medical records or provided by Chang Gung Memorial Hospital Cancer Center.

**Preoperative Evaluation**

Preoperative MRI imaging with and without gadolinium was performed within the 2 weeks prior to surgery. Preoperative clinical evaluations, which included basic neurological and physical examinations and Karnofsky Performance Score (KPS) were performed by the surgeon. For the patients who planned to receive AC, baseline language and neurophysiological examinations were performed and rehearsed by the AC team, which included a neurologist, psychiatrist and speech therapist in order to determine the patients’ suitability for the procedure.

**Intraoperative Technique**

Neuronavigation (Metronic) was used in all cases, and helped to plan the scalp incision. For every case, the craniotomy exposed the lesion plus about a 1- to 3-cm margin that allowed for mapping of the nearby functional cortex. The monitored anesthesia care technique was used for sedation for patients undergoing AC. A complete scalp block was applied using 2% lidocaine with 1:200000 epinephrine. The patient was placed in the supine position, and a skull clamp was employed to position the head optimally for surgery. Upon removal of the bone flap, the patient was allowed to wake up. Local anesthetic was applied again with a 30-gauge needle into the dural leaflets, and the dura was opened in a manner to expose the lesion.

Stimulation mapping then followed using an Ojemann cortical stimulator (Radionics Inc., Burlington, Mass., USA). The initial setting was 5 mA and was increased to a maximum of 10 mA until motor or sensory function was found or after discharge potentials were detected. A current generator delivered biphasic square waves at a pulse duration of 0.5 ms and pulse rate of 50 Hz as previously reported.\(^{13,14}\) Stimulation was applied for 2 to 3 s at the indicated sites, with a 4 to 10 s pause between stimulations. Both the cortical and subcortical regions were identified using the same stimulation technique.
For motor mapping, the area of interest was stimulated and the patient or rehabilitation physician reported whether there was any movement of the arm, leg, or face. Positive stimulation sites were repeated up to 3 times to verify the location. Negative sensorimotor mapping was indicated when no positive stimulation response occurred at the areas of interest.

For language mapping, the area of interest was stimulated and the patient or rehabilitation physician reported whether there was any abnormal number counting or visual object naming. During this time, we also performed continuous motor function testing. During surgical resection, continuous functional monitoring was performed using the object naming task and continuous motor function testing.

For surgery under GA, somatosensory evoked potentials were applied preoperatively and phase reversal was used to help localize the motor strip prior to the corticectomy. In stimulation mapping for surgery under GA, the Ojemann cortical stimulator (Radionics Inc., Burlington, Mass., USA) was used in a similar manner to AC. A biphasic square wave pulse was delivered at a brief intermittent current varying from 2 to 8 mA to elicit a motor response. A multichannel electromyography recording was used to identify motor responses during the procedure.

**Tumor Volume Analysis**

The preoperative tumor volume was determined using T1-weighted MRI with gadolinium contrast for high-grade glioma. After surgery, all patients were admitted to the neurosurgical intensive care unit (NSICU). Postoperative MRI was performed within 48 hours to determine the quality of tumor removal. The extent of tumor resection was assessed by a neuroradiologist according to the classification system reported by Sawaya et al.: (i) gross total resection (GTR) was achieved if > 95% of the tumor was removed; (ii) subtotal resection (STR) if 85–95% was removed; (iii) or partial resection (PR) if < 85% of the tumor was removed.17

**Outcome Evaluation**

The patients who underwent AC with intraoperative stimulation mapping and those who underwent conventional craniotomy under GA were identified according to surgical records. The primary outcome was the postoperative KPS, which was defined as the general daily performance status score recorded...
within 3 months after surgery. Secondary outcomes in this study were progression-free survival (PFS), which was defined as the duration from diagnosis to either disease progression or the latest follow-up imaging study if no disease progression had been observed, and OS, which was defined as the duration from diagnosis to either death or the latest follow-up.

Statistical Analysis

The patients were stratified into AC and GA groups. The Student’s t test, \(X^2\) test and Fisher’s exact test were used to examine the associations between demographic and clinical factors. Survival curves were estimated using the Kaplan-Meier method. To test whether AC was an independent prognostic factor of OS, a multivariate Cox proportional hazard model was used. The level of significance was set at 0.05, and all tests were performed using IBM, SPSS version 21.

Results

Patient Characteristics

One-hundred and nine patients were treated for left hemispheric eloquent gyrus, glioblastoma between 2008 and 2018 at our institution, of whom 61 underwent surgery under GA and 48 underwent AC. The demographics and preoperative comorbidities are shown in Table 1. Preoperative functional activity according to KPS was similar between the GA and AC groups (Table 1).

Tumor Characteristics

There were no significant differences in the tumor location including the primary motor cortex (GA vs AC, 67.2% vs 54.2%; \(p=0.165\)), primary sensory cortex (GA vs AC, 6.6% vs 12.5%; \(p=0.286\)), premotor cortex (GA vs AC, 6.6% vs 8.3%; \(p=0.724\)), and language cortex (GA vs AC, 19.7% vs 22.9%; \(p=0.68\)) between the two groups. There was also no significant difference in first, second, or third surgeries (GA vs AC, 83.6% vs 85.4%; 13.1% vs 8.3%; and 3.3% vs 6.3%, respectively, \(p=0.581\)) (Table 2).

Extent of Resection

Twenty-eight (45.7%) patients in the GA group achieved GTR compared to 40 (83.3%) patients in the AC group. Eighteen (29.5%) patients in the GA group achieved STR compared to six (12.5%) in the AC group, and 15 (24.6%) patients in the GA group achieved PR compared to two (4.2%) in the AC group.
There was a significant difference in the percentage of resection between the two groups (p<0.0001) (Table 3).

The mean preoperative tumor volume in the GA and AC groups were similar (42.5mm$^3$ +/- 11.8 vs 43.6mm$^3$ +/- 10.2, p=0.155). The mean EOR in the GA group was 90.2% compared to 94.9% in the AC group (p=0.003, Table 3).

Table 4 shows the different EOR between the GA and AC groups according to tumor location. There was a significantly different EOR between the two groups in tumors located in the language cortex (p<0.001), but there were no significant differences in tumors located in the primary motor cortex, primary sensory cortex, or premotor cortex.

**Postoperative Functional Outcomes**

We defined KPS 80-100 as a good functional outcome and KPS < 80 as a bad functional outcome, and there was a significant difference in postoperative KPS between the two groups (p=0.002) (Table 6).

**Progression-Free Survival**

There was a significant difference in PFS between the GA group and AC group (p=0.001) (Fig. 1). The mean PFS was 18.9 months in the GA group and 23.2 months in the AC group.

**Overall Survival**

There was a significant difference in OS between the GA group and AC group (p<0.001) (Fig. 2). The mean OS was 25.5 months in all patients, 23.4 months in the GA group, and 28.1 months in the AC group. Tables 5 and 6 show the results of univariate and multivariate analyses for the factors associated with OS, respectively. Better OS was not significantly associated with age, gender, preoperative KPS, or postoperative KPS in univariate Cox proportional hazard analysis, however AC (OR 2.366; 95% CI 1.466-3.817; p < 0.001, univariate logistic regression), the percentage of resection (STR vs GTR, OR 0.104; 95% CI 0.077-0.255, p < 0.001; PR vs STR, OR 0.265; 95% CI 0.135-0.518, p < 0.001 univariate logistic regression), and the EOR (OR 0.913; 95% CI 0.887-0.938; p < 0.001, univariate logistic regression) were associated with better OS. In multivariate analysis, the EOR and
preoperative KPS were independently associated with better OS (Table 6).

Discussion
Both AC and surgery under GA are viable options to treat left hemispheric glioblastoma in eloquent regions of the brain. To the best of our knowledge, this is the largest study to compare the feasibility, postoperative functional outcomes, progression free survival and overall survival of GA and AC for single hemisphere, single pathology glioblastoma in eloquent regions of the brain. Despite advances in functional MRI and neuronavigation techniques that allow for anatomic localization of brain function under general anesthesia, real-time feedback regarding the patient’s neurological status remains a distinct advantage of the AC procedure. Brain mapping during removal of intra-axial tumors enables surgeons to reduce the risk of morbidity. AC is a practical and effective standard surgical approach for supratentorial intrinsic eloquent area lesions, and it is an excellent alternative to craniotomy under GA because it allows for brain mapping and avoids the risks associated with GA. Our results showed that compared to surgery under GA, AC for glioblastoma resulted in a higher frequency of radiographic total resection of enhanced tumors, better KPS within 3 months after surgery, and also better PFS and OS.

Extent of Resection
At least STR was achieved in more than 90% of the glioblastoma patients in the AC group. However, comparisons of the EOR between different studies is difficult because this highly depends on localization, tumor burden, and functional reorganization. Many studies have reported resection rates and the merits of AC. Gupta et al. reported that complete resection was achieved in 47.6% of patients who underwent AC, and also that complete/gross total tumor excision was achieved in a greater number of patients who underwent GA (63%) than AC (47%). In addition, Meyer et al. reported that GTR was achieved in 52% of their patients who underwent AC. However, these studies included either different pathologies or varying grades of glioma. In the present study, only glioblastoma patients were included, and all of the lesions were in left hemispheric eloquent regions. The average EOR was 94.9%, and 83.3% of the patients achieved GTR
in the AC group which was a very convincing result showing that AC can improve the tumor resection rate (Table 3). Furthermore, we also compared the EOR between the GA and AC groups according to the tumor location, and the results were interesting but not surprising. The mean EOR was significantly lower in the GA group (80.08%) for tumors located within the language cortex compared to the AC group (93.9%) (p<0.001). This finding is compatible with the study of Sawaya et al., in which tumor functional grade was the most important variable for determining the risk of a new neurological deficit after surgery. To preserve neurological function, tumors in eloquent brain areas can only be biopsied or partially resected, whereas lesions in non-eloquent brain regions can be more aggressively resected. Thus, when evaluating associations between survival and surgical treatment, it is important to take the tumor location into account. We hypothesize that one of the main causes of this difference may be because language function is very complex and hard to monitor using only cortical and subcortical stimulation during surgery. The most accurate and direct method to monitor language is to interact with the patient. Second, since the language region could not be accurately identified from the information provided from neurophysical monitoring in the GA group, the surgeon would perform relatively conservative tumor resection to prevent the occurrence of new neurological deficits.

**Progression-free Survival and Overall Survival**

There were significant differences in both PFS and OS between the AC and GA groups in this study. To the best of our knowledge, these two major outcomes are fully dependent on the EOR. The mean OS was 25.5 months in the overall cohort, and 30 months and 24.7 months in the patients with GTR and STR, respectively. These results are similar to those of Bloch et al., who reported OS ranging from 18.4 months to 20.4 months depending on the EOR. In their study, only 48.6% of the patients achieved GTR initially and the remaining patients achieved STR (51.4%), which is lower than in our study (Table 3).

The optimal EOR in any patient depends on the tumor size and location, the patient’s general and neurological status, and the experience of the surgeon. Lacroix et al. reported that the EOR in
patients with glioblastoma began to be associated with a survival advantage at 89% of the tumor volume. In addition, aggressive resection of 98% or more of the tumor volume was a significant independent predictor of patient survival. In the field of neuro-oncology, many large retrospective cohort studies have also demonstrated enhanced survival with increased EOR in patients with newly diagnosed GBM, and mathematical modeling of retrospective data suggests incremental improvements in survival with EORs ranging from 78% to 98%. In this study, the mean EOR in both groups (GA vs. AC, 90.2% vs. 94.9, respectively) also reached 89%, the threshold of survival advantage.

Some previous studies have reported that age is the most important prognostic factor associated with OS in glioblastoma patients, and other studies have suggested that female glioblastoma patients have a better OS. However, in the present study, neither age nor gender was a significant prognostic factor for OS in multivariate analysis (p=0.074 and 0.08, respectively) (Table 6). With regards to KPS, some studies have suggested that with the current clinical armamentarium, glioblastoma patients with a preoperative KPS <60 are unlikely to survive >5 years. In this study, we demonstrated that preoperative KPS was an independent predictive factor of OS (Table 6).

**Postoperative Characteristics**

In this study, there was no difference in the distribution of preoperative KPS between the AC and GA groups, however there were differences after surgery (Table 7). The proportion of patients with a postoperative KPS >80 increased from 70.8% to 85.4%. This result indicates that AC may not only preserve a patient’s neurological functional activities, but also that intact neurological function can further improve a patient’s general performance status for daily activities.

Our results also showed that the immediate postoperative neurological function in the AC group was significantly better than that in the GA group. Furthermore, in the first few days (within 3-7 days), the KPS in the AC group was even better. It has been shown that mild to moderate postoperative neurological deficits secondary to aggressive tumor debulking in an AC can quickly recover over several days. This clinical finding is compatible with the concept of “brain plasticity” proposed
by Duffau.35

Limitations

First, selection bias and a lack of randomization are limitations of this retrospective study. Second, due to the inclusion criteria, the number of case numbers was not large. Third, the prognosis of GBM is influenced by molecular markers including IDH1 and MGMT, however we lacked information on these markers. Fourth, patients undergoing AC require both the ability to and willingness to participate in the operation, and this may be a source of selection bias. A well-designed prospective validation study with independent cohorts is needed to verify our results.

Conclusions

In summary, we demonstrated that AC can be performed in adult patients with left hemispheric eloquent GBM, with a better postoperative KPS, better PFS and OS compared with surgery under GA. We also found that preoperative KPS and EOR were the most important independent prognostic factors of survival. We recommend AC as standard care for patient with left hemispheric eloquent GBM if the resources are available.

List Of Abbreviations

AC: Awake craniotomy; GA: General anesthesia; PFS: progression-free survival; OS: overall survival; EOR: extent of resection; KPS: Karnofsky Performance Status; GTR: gross total resection; STR: subtotal resection

Declarations

Ethics approval and consent to participate

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional or national research committee of Chang Gung Medical Foundation Institutional Review Board, and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Consent for Publication

The authors understand that the Publisher may grant these same rights to Journal. Additionally, the authors also grant the right to both Journal and Publisher to enter into agreements with third party entities that grant such third party entities any or all of the rights that the authors have granted to
Publisher herein. The aforementioned rights may include the rights necessary to index and abstract the Submission.

The authors agree that any subsequent publication of the Submission will credit the Journal as the site of first publication and provide a link to the Journal website.

Authors:
Ying-Ching Li
Hsiao-Yean Chiu
Kuo-Chen Wei
Ya-Jui Lin
Ko-Ting Chen
Peng-Wei Hsu
Yin-Cheng Huang
Pin-Yuan Chen

**Availability of data and materials**

All data generated or analysed during this study are included in this published article.

**Competing interests**

The authors declare to have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article. There is no conflict of interest.

**Funding**

Not applicable.

**Authors' contributions**

Ying-Ching Li : Conception and design, Statistical analysis, Drafting the article

Hsiao-Yean Chiu: Statistical analysis

Kuo-Chen Wei: Study supervision

Ya-Jui Lin: Study supervision

Ko-Ting Chen: Study supervision

Peng-Wei Hsu : Study supervision
Yin-Cheng Huang: Study supervision
Pin-Yuan Chen: Critically revising the article, Study supervision

*All authors have read and approved the manuscript

Acknowledgements

The study was supported by Chang Gung Medical Foundation Grant CMRPG2J0111 / CMRPG2G0723

References

1. Hervey-Jumper SL, Li J, Lau D, et al. Awake craniotomy to maximize glioma resection: methods and technical nuances over a 27-year period. *J Neurosurg*. 2015;123(2):325-339. doi:10.3171/2014.10.JNS141520

2. Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. *JAMA - J Am Med Assoc*. 2012. doi:10.1001/jama.2012.12807

3. Markert JM. The role of early resection vs biopsy in the management of low-grade gliomas. *JAMA - J Am Med Assoc*. 2012. doi:10.1001/jama.2012.14523

4. McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas. *Neurosurgery*. 2008. doi:10.1227/01.NEU.0000325729.41085.73

5. Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. *J Clin Oncol*. 2008. doi:10.1200/JCO.2007.13.9337

6. Trimble G, McStravick C, Farling P, et al. Awake craniotomy for glioma resection: Technical aspects and initial results in a single institution. *Br J Neurosurg*. 2015. doi:10.3109/02688697.2015.1054354

7. Almeida JP, Chaichana KL, Rincon-Torroella J, Quinones-Hinojosa A. The Value of Extent of Resection of Glioblastomas: Clinical Evidence and Current Approach. *Curr
8. Chaichana KL, Jusue-Torres I, Lemos AM, et al. The butterfly effect on glioblastoma: is volumetric extent of resection more effective than biopsy for these tumors? *J Neurooncol.* 2014. doi:10.1007/s11060-014-1597-9

9. Chaichana KL, Cabrera-Aldana EE, Jusue-Torres I, et al. When Gross Total Resection of a Glioblastoma Is Possible, How Much Resection Should Be Achieved? *World Neurosurg.* 2014. doi:10.1016/j.wneu.2014.01.019

10. Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. *Neuro Oncol.* 2014. doi:10.1093/neuonc/not137

11. Skirboll SS, Ojemann GA, Berger MS, Lettich E, Winn HR. Functional cortex and subcortical white matter located within gliomas. *Neurosurgery.* 1996. doi:10.1227/00006123-199604000-00008

12. Ojemann JG, Miller JW, Silbergeld DL. Preserved function in brain invaded by tumor. *Neurosurgery.* 1996. doi:10.1097/00006123-199608000-00003

13. Walker JA, Quiñones-Hinojosa A, Berger MS, Grossman RG. Intraoperative Speech Mapping in 17 Bilingual Patients Undergoing Resection of a Mass Lesion. *Neurosurgery.* 2004. doi:10.1227/01.NEU.0000097270.95721.3B

14. Quiñones-Hinojosa A, Ojemann SG, Sanai N, Dillon WP, Berger MS. Preoperative correlation of intraoperative cortical mapping with magnetic resonance imaging landmarks to predict localization of the Broca area. *J Neurosurg.* 2003. doi:10.3171/jns.2003.99.2.0311

15. Brown T, Shah AH, Bregy A, et al. Awake Craniotomy for Brain Tumor Resection. *J Neurosurg Anesthesiol.* 2013;25(3):240-247. doi:10.1097/ANA.0b013e318290c230
16. Boetto J, Bertram L, Moulinié G, Herbet G, Moritz-Gasser S, Duffau H. Low rate of intraoperative seizures during awake craniotomy in a prospective cohort with 374 supratentorial brain lesions: Electrocorticography is not mandatory. *World Neurosurg.* 2015;84(6):1838-1844. doi:10.1016/j.wneu.2015.07.075

17. Sawaya R, Hammoud M, Schoppa D, et al. Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. *Neurosurgery.* 1998;42(5):1044-1056. doi:10.1097/00006123-199805000-00054

18. Gonen T, Grossman R, Sitt R, et al. Tumor location and IDH1 mutation may predict intraoperative seizures during awake craniotomy. *J Neurosurg.* 2014. doi:10.3171/2014.7.JNS132657

19. Sacko O, Lauwers-Cances V, Brauge D, Sesay M, Brenner A, Roux FE. Awake craniotomy vs surgery under general anesthesia for resection of supratentorial lesions. *Neurosurgery.* 2011;68(5):1192-1198. doi:10.1227/NEU.0b013e31820c02a3

20. Ebeling U, Schmid UD, Ying H, Reulen HJ. Safe surgery of lesions near the motor cortex using intra-operative mapping techniques: a report on 50 patients. *Acta Neurochir (Wien).* 1992;119(1-4):23-28. doi:10.1007/BF01541777

21. Nossek E, Matot I, Shahar T, et al. Intraoperative seizures during awake craniotomy: Incidence and consequences: Analysis of 477 patients. *Neurosurgery.* 2013;73(1):135-140. doi:10.1227/01.neu.0000429847.91707.97

22. Mandonnet E, De Witt Hamer P, Poisson I, et al. Initial experience using awake surgery for glioma: Oncological, functional, and employment outcomes in a consecutive series of 25 cases. *Neurosurgery.* 2015. doi:10.1227/NEU.0000000000000644

23. Gupta DK, Chandra PS, Ojha BK, Sharma BS, Mahapatra AK, Mehta VS. Awake craniotomy versus surgery under general anesthesia for resection of intrinsic lesions
of eloquent cortex-A prospective randomised study. *Clin Neurol Neurosurg.* 2007;109(4):335-343. doi:10.1016/j.clineuro.2007.01.008

24. Meyer FB, Bates LM, Goerss SJ, et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent brain. *Mayo Clin Proc.* 2001;76(7):677-687. doi:10.4065/76.7.677

25. Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: Clinical article. *J Neurosurg.* 2012. doi:10.3171/2012.9.JNS12504

26. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, and survival. *J Neurosurg.* 2001. doi:10.3171/jns.2001.95.2.0190

27. Brown TJ, Brennan MC, Li M, et al. Association of the extent of resection with survival in glioblastoma a systematic review and meta-Analysis. *JAMA Oncol.* 2016;2(11):1460-1469. doi:10.1001/jamaoncol.2016.1373

28. Shinojima N, Kochi M, Hamada JI, et al. The influence of sex and the presence of giant cells on postoperative long-term survival in adult patients with supratentorial glioblastoma multiforme. *J Neurosurg.* 2004. doi:10.3171/jns.2004.101.2.0219

29. Adeberg S, Bostel T, König L, Welzel T, Debus J, Combs SE. A comparison of long-term survivors and short-term survivors with glioblastoma, subventricular zone involvement: A predictive factor for survival? *Radiat Oncol.* 2014. doi:10.1186/1748-717X-9-95

30. Geisenberger C, Mock A, Warta R, et al. Molecular profiling of long-term survivors identifies a subgroup of glioblastoma characterized by chromosome 19/20 co-gain. *Acta Neuropathol.* 2015. doi:10.1007/s00401-015-1427-y

31. Krex D, Klink B, Hartmann C, et al. Long-term survival with glioblastoma multiforme. *Brain.* 2007. doi:10.1093/brain/awm204
32. Nakagawa Y, Sasaki H, Ohara K, et al. Clinical and Molecular Prognostic Factors for Long-Term Survival of Patients with Glioblastomas in Single-Institutional Consecutive Cohort. *World Neurosurg.* 2017;106:165-173. doi:10.1016/j.wneu.2017.06.126

33. Duffau H. A new concept of diffuse (low-grade) glioma surgery. *Adv Tech Stand Neurosurg.* 2012. doi:10.1007/978-3-7091-0676-1_1

34. Beez T, Boge K, Wager M, et al. Tolerance of awake surgery for glioma: A prospective European Low Grade Glioma Network multicenter study. *Acta Neurochir (Wien).* 2013;155(7):1301-1308. doi:10.1007/s00701-013-1759-0

35. Duffau H. Brain plasticity: From pathophysiological mechanisms to therapeutic applications. *J Clin Neurosci.* 2006. doi:10.1016/j.jocn.2005.11.045

Tables

**Table 1.** Demographic characteristics of the 109 patients who underwent resection for left hemispheric eloquent region glioblastoma
| Characteristics, n (%)                              | Type of Surgery |
|---------------------------------------------------|-----------------|
|                                                   | GA (n = 61)     | AC (n = 48) | P-value |
| Age at surgery, years (SD)                        | 57.17           | 53.89 (15.4) | 0.344   |
| Gender (Male)                                     | 37 (60.7)       | 28 (58.3)   | 0.806   |
| Preoperative Karnofsky Performance Score (KPS)    | 39 (63.9)       | 34 (70.8)   | 0.447   |
| 100-80, n (%)                                     | 22 (36.1)       | 14 (29.2)   |         |
| 70 or less, n (%)                                 |                 |             |         |
| Comorbidities                                     |                 |             |         |
| Diabetes mellitus, n (%)                          | 4(6.6)          | 4(8.3)      | 0.724   |
| COPD, n (%)                                        | 3(4.9)          | 4(8.3)      | 0.47    |
| Hypertension, n (%)                               | 3(4.9)          | 4(8.3)      | 0.47    |
| CABG/stents, n (%)                                | 0(0)            | 0(0)        | r       |
| Pulmonary emboli, n (%)                           | 0(0)            | 0(0)        | r       |
| Deep venous thromboses, n (%)                     | 0(0)            | 0(0)        | r       |

GA: craniotomy under general anesthesia, AC: awake craniotomy, COPD: chronic obstructive pulmonary disease, CABG: coronary artery bypass graft

**Table 2.** Tumor characteristics of the 109 patients who underwent resection for left hemispheric eloquent region glioblastoma
| Characteristics, n (%) | Type of Surgery |   |   | P-value |
|-----------------------|----------------|---|---|---------|
|                       | GA (n = 61)    | AC (n = 48) |   |         |
| Tumor location, n (%) |               |               |   |         |
| Primary motor cortex  | 41(67.2)       | 26(54.2)      |   | 0.165   |
| Primary sensory cortex| 4(6.6)         | 6(12.5)       |   | 0.286   |
| Premotor cortex       | 4(6.6)         | 4(8.3)        |   | 0.724   |
| Language cortex       | 12(19.7)       | 11(22.9)      |   | 0.68    |
| Resection number, n (%)|               |               |   |         |
| First                 | 51(83.6)       | 41(85.4)      |   | 0.581   |
| Second                | 8(13.1)        | 4(8.3)        |   |         |
| Third or more         | 2(3.3)         | 3(6.3)        |   |         |

**Table 3.** Percent of resection in the 109 patients who underwent resection for left hemispheric eloquent region glioblastoma
| Percentage of resection | Type of Surgery | P-value |
|-------------------------|-----------------|---------|
| Gross total (>95%), n (%) | GA (n = 61) | AC (n = 48) | <0.0001 |
| Subtotal (85-95%), n (%) | 28 (45.9) | 40 (83.3) | |
| Partial (< 85%), n (%) | 18 (29.5) | 6 (12.5) | |
| Partial (< 85%), n (%) | 15 (24.6) | 2 (4.2) | |

| Extent of tumor resection | Type of Surgery | P-value |
|---------------------------|-----------------|---------|
| Preoperative tumor volume mL, mean (SD) | 42.5 (11.8) | 43.6 (10.2) | 0.155 |
| Extent of resection, mean % (SD) | 90.2 (7.44) | 94.9 (5.73) | 0.003 |

**Table 4.** The average extent of resection (EOR) between the GA and AC groups according to tumor location

| Tumor location | Type of Surgery |
|----------------|-----------------|
| Primary motor cortex, patient (n), EOR (%) | 89 | 46, 92.7% | 21, 95% |
| Primary sensory cortex, patient (n), EOR (%) | 10 | 4, 96.5% | 6, 98.5% |
| Premotor cortex, patient (n), EOR (%) | 8 | 4, 96.5% | 4, 93.75% |
| Language cortex, patient (n), EOR (%) | 23 | 12, 80.08% | 11, 93.9% |

**Table 5.** Predictors of overall survival in univariate analysis
### Clinical Data

| Clinical Data                                         | Median Survival (months) |
|-------------------------------------------------------|--------------------------|
| Age, years                                            | 25.53†                   |
| Awake craniotomy, yes                                  | 28.17                    |
| Gender, male vs. female                                | 23.5                     |
| Preoperative KPS, 80-100 vs. ≤70                       | 27.26                    |
| Postoperative KPS, 80-100 vs. ≤70                      | 25.64                    |
| Percentage of resection, subtotal vs. gross total      | 30                       |
| Percentage of resection, partial vs. subtotal          | 24.7                     |
| Extent of resection, %                                 | 25.53†                   |

† Whole cohort.

KPS, Karnofsky Performance Score

### Table 6. Multivariate analysis of overall survival

| Independent Factors                                      | Odds Ratio | 95% CI         | P-value |
|----------------------------------------------------------|------------|----------------|---------|
| Age, years                                               | 1.012      | 0.999-1.026    | 0.07    |
| Awake craniotomy, yes                                    | 0.601      | 0.34-1.06      | 0.08    |
| Gender, male vs. female                                  | 1.32       | 0.822-2.12     | 0.25    |
| Preoperative KPS, 80-100 vs. ≤70                         | 0.422      | 0.22-0.809     | 0.00    |
| Postoperative KPS, 80-100 vs. ≤70                        | 1.494      | 0.772-2.889    | 0.23    |
| Percentage of resection, subtotal vs. gross total        | 0.687      | 0.12-3.93      | 0.67    |
| Percentage of resection, partial vs. subtotal             | 0.56       | 0.178-1.808    | 0.33    |
| Extent of resection, %                                   | 0.914      | 0.841-0.993    | 0.03    |
*All covariates with p value <0.2 in the univariate analysis. According to the multivariate Cox proportional hazard model.

KPS, Karnofsky Performance Score

**Table 7.** Postoperative Karnofsky Performance Score of the 109 patients who underwent brain stimulation for resection of left hemispheric eloquent region glioblastoma

| Characteristics, n (%)                                | Type of Surgery |                  |                  | P-value |
|-------------------------------------------------------|-----------------|------------------|------------------|---------|
|                                                       | GA (n = 61)     | AC (n = 48)      |                  |         |
| Preoperative Karnofsky Performance Score (classification) |                 |                  |                  |         |
| 100-80, n (%)                                         | 39              | 34 (70.8)        |                  | 0.447   |
|                                                       | (63.9)          |                  |                  |         |
| 70 or less, n (%)                                     | 22              | 14 (29.2)        |                  | 0.002   |
|                                                       | (36.1)          |                  |                  |         |
| Postoperative Karnofsky Performance Score (classification) |                 |                  |                  |         |
| 100-80, n (%)                                         | 35              | 41 (85.4)        |                  | 0.000   |
|                                                       | (57.4)          |                  |                  |         |
| 70 or less, n (%)                                     | 26              | 7 (14.6)         |                  | 0.000   |
|                                                       | (42.6)          |                  |                  |         |

Figures
Figure 1
Progression free survival (PFS) in patients with left hemispheric eloquent region glioblastoma (p=0.001)

Figure 2
Overall survival (OS) in patients with left hemispheric eloquent region glioblastoma (p<0.001)
